Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tizita Z. Zeleke"'
Autor:
Erin Honan, Melissa K. Accordino, Ruby Wu, Kathleen Fenn, Tizita Z. Zeleke, Kevin Kalinsky, Cody Chiuzan, Qingfei Pan, Dawn L. Hershman, Jose Silva, Jiyang Yu, Matthew Maurer, Meghna S. Trivedi, Katherin D Crew, Maika Onishi, Sean A. Kelly
Publikováno v:
Cancer Research. 80:P1-19
Background:HDAC6, a cytoplasmic histone deacetylase, impacts cell viability by influencing protein metabolism, microtubule dynamics, and chaperone function. ACY-1215 is an orally active, selective HDAC6 inhibitor. Preclinical studies have demonstrate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1bc3db3a63fee6cdfca548887c81466
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-27
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-27
Autor:
Tizita Z. Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J. Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S. Trivedi, Melissa Accordino, Katherine D. Crew, Dawn L. Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin Kalinsky, Jiyang Yu, Jose Silva
Publikováno v:
Nature cancer.
Inhibiting individual histone deacetylase (HDAC) is emerging as well-tolerated anticancer strategy compared with pan-HDAC inhibitors. Through preclinical studies, we demonstrated that the sensitivity to the leading HDAC6 inhibitor (HDAC6i) ricolinsta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4bb501f66ef195b4fea1214651717ba
https://pubmed.ncbi.nlm.nih.gov/36585452
https://pubmed.ncbi.nlm.nih.gov/36585452
Autor:
Tizita Z. Zeleke, Matthew Maurer, Meghna S. Trivedi, Ruby Wu, Katherine D. Crew, Mariano J. Alvarez, Pei Ling Chia, Sean A. Kelly, Qingfei Pan, Dawn L. Hershman, Min Yang, Andrea Califano, Jiyang Yu, Partha Mukhopadhyay, Melissa Kate Accordino, Maika Onishi, Cody Chiuzan, Erin Honan, Kathleen Fenn, Jose Silva, Simon Jones, Kevin Kalinsky
Publikováno v:
Cancer Research. 81:645-645
Despite the anticancer activity of pan-histone deacetylase (HDAC) inhibitors, their clinical use has been limited due to toxicity. However, the development of more specific inhibitors that selectively inhibit individual HDACs is emerging as a novel a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49f440092b90d67f34cbca89e882bc5e
https://doi.org/10.1158/1538-7445.am2021-645
https://doi.org/10.1158/1538-7445.am2021-645
Autor:
Jose M. Silva, François Bertucci, David Llobet-Navas, Daniel Birnbaum, Ruth Rodriguez-Barrueco, Jiyang Yu, Tizita Z. Zeleke, Erin A. Nekritz, Elena Ezhkova, Carlos Cordon-Cardo, Pascal Finetti, Andrej Gorbatenko, Felix Sanchez-Garcia
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Genes and Development
Genes and Development, 2017, 31 (6), pp.553-566. ⟨10.1101/gad.292318.116⟩
Genes & Development
Genes and Development, Cold Spring Harbor Laboratory Press, 2017, 31 (6), pp.553-566. ⟨10.1101/gad.292318.116⟩
Universidad de Barcelona
Genes and Development
Genes and Development, 2017, 31 (6), pp.553-566. ⟨10.1101/gad.292318.116⟩
Genes & Development
Genes and Development, Cold Spring Harbor Laboratory Press, 2017, 31 (6), pp.553-566. ⟨10.1101/gad.292318.116⟩
International audience; The female mammary gland is a very dynamic organ that undergoes continuous tissue remodeling during adulthood. Although it is well established that the number of menstrual cycles and pregnancy (in this case transiently) increa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::455ea47046205d6fd5dbfdedd75504c7
https://pubmed.ncbi.nlm.nih.gov/28404630
https://pubmed.ncbi.nlm.nih.gov/28404630
Publikováno v:
Cancer Research. 78:2898-2898
The identification and use of biomarkers is critical to guided clinical care. Cancer treatment has made use of many biomarkers to determine which therapeutic avenues are adequate for each patient. For example, the use of Trastuzumab is intimately lin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ee5a35447dbe3caeadd95ab342b75f0
https://doi.org/10.1158/1538-7445.am2018-2898
https://doi.org/10.1158/1538-7445.am2018-2898
Autor:
Tizita Z. Zeleke, Hadassa Hirschfield, Venugopalan D. Nair, C Billie Bian, Yujin Hoshida, Takaaki Higashi, Shigeki Nakagawa, Bryan C. Fuchs
Publikováno v:
Experimental & Molecular Medicine
Tractable experimental model that accounts for inter-tumor molecular heterogeneity is a key element of anti-cancer drug development. Hepatocellular carcinoma is known to exhibit highly heterogeneous molecular aberrations across the tumors, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d66781c56a03ef45294027306caf96f